Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

February 8, 2024: onthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
Press Releases
January 22, 2024: MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
Press Releases
January 8, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Press Releases
December 12, 2023: MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations
Press Releases
December 11, 2023: MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023

See more

Media Coverage

Media

January 21, 2024: Le microbiote à l’attaque du cancer – Les Echos Investir (French only)

Media
December 21, 2023: MaaT Pharma et Skyepharma mettent en service leur usine de médicaments à base de microbiote – Les Echos (French only)
Media
December 18, 2023: Microbiome-based treatment shows potential in graft-versus-host disease – BioPharma reporter
Media
December 11, 2023: ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease – EPR
Media
December 11, 2023: MaaT Pharma : dans la maladie aigüe du greffon contre l’hôte, MaaT Pharma annonce des résultats prometteurs – BFM Bourse (French only)
Media
December 5, 2023: En Isère, au cœur du nouveau site de MaaT Pharma pour produire son traitement microbiote – L’Usine Nouvelle (French only)

See more

Videos

R&D Day 2022 replay

On June 7th, 2022, MaaT Pharma hosted its virtual R&D Day to share the latest…
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année
Videos
Hybridays 2021: Savita BERNAL, Chief Business Officer at MaaT Pharma

Posters

Posters

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

Posters
A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial
Posters
Robust Machine Learning (ML) approach for Screening Microbiome Ecosystem Therapies (MET) Drug Candidates in combination with Immune Checkpoint Inhibitors
Posters
Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
Posters
Benchmarking of shotgun metagenomics analysis results obtained with state-of-the-art optimized pipelines on simulated gut microbiome samples
Posters
Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial